News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sapphire Therapeutics, Inc. to Present Results From Anamorelin Phase 2 Cachexia/Anorexia Studies at American Society of Clinical Oncology and Endocrine Society Annual Meetings in June



4/26/2007 10:27:29 AM

BRIDGEWATER, NJ -- (MARKET WIRE) -- April 26, 2007 -- Sapphire Therapeutics, Inc., a private biopharmaceutical company that develops compounds acting within the ghrelin pathway to treat metabolic and oncologic diseases, has announced that results from Phase 2 studies of anamorelin (formerly known as RC-1291) in cancer cachexia/anorexia subjects in the United States have been accepted for presentation at the 2007 annual meetings of the American Society for Clinical Oncology (ASCO) (June 1-5 in Chicago) and of the Endocrine Society (ENDO) (June 2-5 in Toronto). The presentation at ASCO will disclose the results from a 12-week randomized study comparing anamorelin treatment to placebo in cancer patients; the ENDO presentation will reveal data from a short-term crossover study in cancer patients.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES